Please confirm you are human (Sign Up for free to never see this)
← Back to Search
MRI Contrast Agents: Basic Chemistry And Safety
D. Hao, T. Ai, F. Goerner, X. Hu, V. Runge, M. Tweedle
Published 2012 · Chemistry, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Magnetic resonance imaging (MRI) contrast agents are pharmaceuticals used widely in MRI examinations. Gadolinium‐based MRI contrast agents (GBCAs) are by far the most commonly used. To date, nine GBCAs have been commercialized for clinical use, primarily indicated in the central nervous system, vasculature, and whole body. GBCAs primarily lower the T1 in vivo to create higher signal in T1‐weighted MRI scans where GBCAs are concentrated. GBCAs are unique among pharmaceuticals, being water proton relaxation catalysts whose effectiveness is characterized by a rate constant known as relaxivity. The relaxivity of each GBCAs depends on a variety of factors that are discussed in terms of both the existing agents and future molecular imaging agents under study by current researchers. Current GBCAs can be divided into four different structural types (macrocyclic, linear, ionic, and nonionic) based on the chemistry of the chelating ligands whose primary purpose is to protect the body from dissociation of the relatively toxic Gd3+ ion from the ligand. This article discusses how the chemical structure influences inherent and in vivo stability toward dissociation, and how it affects important formulation properties. Although GBCAs have a lower rate of serious adverse events than iodinated contrast agents, they still present some risk. J. Magn. Reson. Imaging 2012;36:1060–1071. © 2012 Wiley Periodicals, Inc.
This paper references
Next generation, high relaxivity gadolinium MRI agents.
K. Raymond (2005)
"Stability" of gadolinium chelates.
M. Tweedle (2007)
Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications.
P. Caravan (1999)
Gd(DOTP)5‐ outer‐sphere relaxation enhancement promoted by nitrogen bases
S. Aime (1993)
Present aspects of MRI contrast agents — early experience with DOTA gadolinium. In: ‘‘MR 85’
B Bonnemain (1985)
Biochemical safety profiles of gadolinium‐based extracellular contrast agents and nephrogenic systemic fibrosis
Hale Ersoy (2007)
Contrast enhanced MRI. Evaluation of a canine model of osmotic blood-brain barrier disruption.
V. Runge (1985)
Present aspects of MRI contrast agents — early experience with DOTA gadolinium
B Bonnemain (1985)
Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents
H. Pietsch (2009)
Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C
T. Frenzel (2008)
Clinical Safety and Diagnostic Value of the Gadolinium Chelate Gadoterate Meglumine (Gd-DOTA)
C. Herborn (2007)
Assessment of Utilization and Pharmacovigilance Based on Spontaneous Adverse Event Reporting of Gadopentetate Dimeglumine as a Magnetic Resonance Contrast Agent After 45 Million Administrations and 15 Years of Clinical Use
M. Knopp (2006)
Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats
M. Tweedle (1995)
Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents.
S. Laurent (2006)
Local Tissue Toxicity in Response to Extravascular Extravasation of Magnetic Resonance Contrast Media
V. Runge (2002)
Gadodiamide administration causes spurious hypocalcemia.
M. Prince (2003)
Quantitative dependence of MR signal intensity on tissue concentration of Gd(HP-DO3A) in the nephrectomized rat.
P. Wedeking (1992)
Extracellular gadolinium contrast agents: differences in stability.
S. Morcos (2008)
Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review
M. Port (2008)
MR appearance of extravasated gadolinium contrast medium.
D. A. Carrier (1993)
Effect of Ligand Basicity on the Formation and Dissociation Equilibria and Kinetics of Gd3+ Complexes of Macrocyclic Polyamino Carboxylates
K. Kumar (1994)
Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 Tesla
J. Pintaske (2006)
Nephrogenic systemic fibrosis is found only among gadolinium‐exposed patients with renal insufficiency: a case–control study from Denmark
T. R. Elmholdt (2011)
Considerations involving paramagnetic coordination compounds as useful NMR contrast agents.
M. Tweedle (1988)
Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensinconverting enzyme
C Corot (1998)
Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value.
J. Emerson (2004)
Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide
H. Thomsen (2006)
Gadolinium‐based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand
M. Sieber (2008)
Physicochemical properties of gadoteridol and other magnetic resonance contrast agents.
M. Tweedle (1992)
Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients.
D. Morgan (2011)
MRI contrast agents: current status and future perspectives.
G. Strijkers (2007)
Incidence of immediate gadolinium contrast media reactions.
M. Prince (2011)
Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent.
H. J. Weinmann (1984)
Stability of linear and macrocyclic gadolinium based contrast agents.
H. Schmitt-Willich (2007)
Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
J. Idée (2009)
Clinical and histological findings in nephrogenic systemic fibrosis.
S. Cowper (2008)
The use of molecular descriptors in the design of gadolinium (III) chelates as MRI contrast agents.
A. Maiocchi (2003)
Dissociation of gadolinium chelates in mice: relationship to chemical characteristics.
P. Wedeking (1992)
Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients.
M. Maurer (2012)
The relationship between thermodynamics and the toxicity of gadolinium complexes.
W. Cacheris (1990)
Synthesis and Physicochemical Characterization of a New Gadolinium Chelate: The Liver-Specific Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA.
H. Schmitt-Willich (1999)
Nephrogenic systemic fibrosis: a chemical perspective.
N. Rofsky (2008)
Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium.
P. Normann (1995)
A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media
M. Sieber (2008)
Preparation and water relaxation properties of proteins labeled with paramagnetic metal chelates.
R. Lauffer (1985)
Reaction of gadolinium chelates with endogenously available ions.
M. Tweedle (1991)
Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.
J. Idée (2008)
The ProHance story: the making of a novel MRI contrast agent
M. Tweedle (1997)
Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy
G. White (2006)
Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths
M. Rohrer (2005)
Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
Rebecca Wertman (2008)
Gd-DOTA: characterization of a new paramagnetic complex.
J. C. Bousquet (1988)
Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections.
H. Abujudeh (2010)
Comparative Chemical Structure and Pharmacokinetics of MRI Contrast Agents
M. Tweedle (1988)
Clinical MRI. Philadelphia: Saunders; 2002. p 454–457
VM Runge (2002)
Gadolinium and nephrogenic systemic fibrosis.
V. Runge (2009)
trast enhanced MRI . Evaluation of a canine model of osmotic blood - brain barrier disruption
VM Runge (1985)
Comparison of magnetic properties of MRI contrast media 1070 Hao et al. solutions at different magnetic field strengths
M Rohrer (2005)
Measurement of serum calcium concentration after administration of gadoversetamide in dogs.
J. Wible (2004)
X-Ray Contrast Media Mechanisms in the Release of Mast Cell Contents: Understanding These Leads to a Treatment for Allergies
E. Lasser (2011)
Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy
W. Gibby (2004)
Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (GdDOTA)
CU Herborn (2007)
pH dependence of relaxivities and hydration numbers of gadolinium(III) complexes of linear amino carboxylates
CA BHChang (1990)
MS-325: albumin-targeted contrast agent for MR angiography.
R. Lauffer (1998)
ACR guidance document for safe MR practices: 2007.
E. Kanal (2007)
Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine.
A. G. Bleicher (2008)
What nephrologists need to know about gadolinium
J. G. Penfield (2007)
The design of molecular hosts, guests, and their complexes.
D. Cram (1988)
Allergic reactions to gadolinium chelates.
V. Runge (2001)
Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation
J. Idée (2004)
Stability of MRI Paramagnetic Contrast Media: A Proton Relaxometric Protocol for Transmetallation Assessment
S. Laurent (2001)
Structure‐activity relationship of macrocyclic and linear gadolinium chelates: Investigation of transmetallation effect on the zinc‐dependent metallopeptidase angiotensin‐converting enzyme
C. Corot (1998)
The Gd(3+) complex of a fatty acid analogue of DOTP binds to multiple albumin sites with variable water relaxivities.
P. Caravan (2001)
Nephrogenic systemic fibrosis: risk factors and incidence estimation.
E. Sadowski (2007)
Bioresponsive, cell-penetrating, and multimeric MR contrast agents.
Jody L. Major (2009)
New insights into nephrogenic systemic fibrosis.
S. Swaminathan (2007)
The Shape of Things To Come
M. H. Schreiber (1988)
MR contrast agents: Physical and pharmacologic basics
Shao-Pow Lin (2007)
pH dependence of relaxivities and hydration numbers of gadolinium(III) complexes of macrocyclic amino carboxylates
X. Zhang (1990)
Synthesis and physicochemical characterization of a new gadolinium chelate: the liver-specific magnetic resonance imaging contrast agent GdEOB-DTPA
H Schmitt-Willich (1999)
V M Runge (2002)
A new lipophilic gadolinium chelate as a tissue‐specific contrast medium for MRI
H. Weinmann (1991)
Contrast Media in Magnetic Resonance Imaging
A. Aisen (1994)
Enhanced Magnetic Resonance Imaging
Jr Amil J. Gerlock (1990)
This paper is referenced by
i ntracranial gadolinium Deposition after contrast-enhanced M
R. McDonald (2015)
Gadolinium deposition in the brain.
T. Kanda (2016)
Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns
R. Forghani (2016)
Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.
R. McDonald (2018)
Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus
V. Runge (2016)
Iron(III) Contrast Agent Candidates for MRI: a Survey of the Structure–Effect Relationship in the Last 15 Years of Studies
N. Kuźnik (2016)
Gadolinium-Based Contrast Agents: Associated Adverse Reactions.
M. Ramalho (2017)
PEGylated chitosan grafted with polyamidoamine-dendron as tumor-targeted magnetic resonance imaging contrast agent
Guangyue Zu (2017)
Gadolinium Deposition in Humans: When Did We Learn That Gadolinium Was Deposited In Vivo?
James E. Huckle (2016)
Gadolinium in Humans: A Family of Disorders.
R. Semelka (2016)
Balancing the intermolecular forces in peptide amphiphiles for controlling self-assembly transitions.
C. Buettner (2017)
[Acquisition of Pulmonary Vein and Left Atrium with Trigger Angiography Non-contrast Enhanced MRI in Diastolic Phase].
Tomofumi Misaka (2019)
Multiparametric and multidimensional: a three-dimensional and multiparametric approach to ultrasound imaging of prostate cancer
R. Wildeboer (2019)
Gadolinium as an Emerging Microcontaminant in Water Resources: Threats and Opportunities
P. Ebrahimi (2019)
Comparison of the Relaxivities of Macrocyclic Gadolinium-Based Contrast Agents in Human Plasma at 1.5, 3, and 7 T, and Blood at 3 T
P. Szomolanyi (2019)
Brain Imaging in Psychiatry
D. Lehrer (2015)
Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents
Lara Chehabeddine (2019)
Erratum to: Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5 years
M. Kromrey (2016)
High‐Contrast Magnetic Resonance Imaging and Efficient Delivery of an Albumin Nanotheranostic in Triple‐Negative Breast Cancer Xenografts
S. Hafner (2019)
Advances in functional and structural imaging of the human lung using proton MRI
G. Miller (2014)
Contrast Media for X-ray and Magnetic Resonance Imaging: Development, Current Status and Future Perspectives
T. Frenzel (2015)
Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance®) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?
M. Kirchin (2015)
Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: a case report and a comprehensive evidence-based review
D. Provenzano (2019)
Iron(III)-Tannic Molecular Nanoparticles Enhance Autophagy effect and T1 MRI Contrast in Liver Cell Lines
Krungchanuchat Saowalak (2018)
Spatially resolved quantification of gadolinium deposited in the brain of a patient treated with gadolinium-based contrast agents.
Stefanie Fingerhut (2018)
Ex vivo gadoxetate relaxivities in rat liver tissue and blood at five magnetic field strengths from 1.41 to 7 T
Sabina Ziemian (2020)
Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy.
Guosong Hong (2015)
Disease course and efficacy of medical therapy in stricturing paediatric Crohn's disease.
M. Aloi (2013)
Sequential Nitration/Hydrogenation Protocol for the Synthesis of Triaminophloroglucinol: Safe Generation and Use of an Explosive Intermediate under Continuous-Flow Conditions
D. Cantillo (2014)
Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.
T. Kanda (2015)
Gadolinium Retention in the Rat Brain: Assessment of the Amounts of Insoluble Gadolinium-containing Species and Intact Gadolinium Complexes after Repeated Administration of Gadolinium-based Contrast Agents.
E. Gianolio (2017)
Imágenes del depósito de gadolinio en el sistema nervioso central
R. Valenzuela (2017)See more